Several of these suggested modes of action, like the boost of ROS production and the interaction with oncogenic NF-KB and/or MAPK pathways might have distinctly stronger impacts on malignant as compared to non-malignant cells and, hence, might contribute to the observed cancer selectivity. This evidence concerns the gene NFKB1 and cancer.